Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F182112 + CD38
- Development stage
- Unknown
- Lead developer
- Shandong New Time Pharmaceutical
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
F182112 + CD38 is an investigational combination therapy being evaluated for the treatment of relapsed or refractory multiple myeloma (RRMM). F182112 is a humanized bispecific antibody developed by Shandong New Time Pharmaceutical (a subsidiary of Lunan Pharmaceutical Group) that targets B-cell maturation antigen (BCMA) on myeloma cells and the CD3 epsilon subunit on T cells, thereby facilitating T-cell mediated cytotoxicity against tumor cells. The combination regimen involves the administration of F182112 alongside a CD38-targeting monoclonal antibody (such as daratumumab). This dual-antigen targeting approach (BCMA and CD38) is intended to enhance anti-tumor efficacy and overcome resistance in patients who have previously failed standard-of-care treatments, including proteasome inhibitors and immunomodulatory drugs (IMiDs). The regimen is currently being studied in Phase II clinical trials (e.g., NCT07312188).
- Other names
- F182112 plus CD38 antibodyF-182112 plus CD38 antibodyF 182112 plus CD38 antibodyF182112 and CD38 antibodyF-182112 and CD38 antibodyF 182112 and CD38 antibody
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on F182112 + CD38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F182112 + CD38.